

RECEIVED
CENTRAL FAX CENTERPATENT
P56874

NOV 22 2006

AMENDMENTS IN THE CLAIMS

Please amend claims 1, 3 and 6, and cancel claim 5 without disclaiming its subject matter, to read as follows:

1. (Currently Amended) A method for controlling chronic inflammation in an individual having Metabolic Syndrome, comprising:
administering to said individual an effective dosage of a pharmaceutical composition selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, and a combination thereof.

2. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by at least one of elevated C-Reactive Protein and elevated serum fibrinogen.

3. (Currently amended) The method of claim 1, wherein the chronic inflammation is evidenced by at least one of elevated platelet count and elevated platelet activity ~~due to the chronic inflammation.~~

4. (Original) The method of claim 1, wherein the individual has at least one condition selected from the group consisting of hypertension, hypercholesterolemia, hypertriglyceridemia, and obesity.

5. (Canceled)

PATENT
P56874

1 6. (Currently Amended) The method of ~~claim 5~~ claim 1, wherein ~~the component of the~~
2 ~~Metabolic syndrome is the individual has at least one condition~~ selected from the group
3 consisting of obesity, insulin resistance, hypertension, dyslipidemia, impaired glucose tolerance,
4 accompanied by increased acute phase proteins including C-Reactive Protein and fibrinogen.

1 7. (Original) The method of claim 1, wherein said individual has diabetes mellitus,
2 coronary artery disease or cancer.

1 8. (Withdrawn) A method for controlling elevated blood glucose level in an individual
2 with inflammation-related metabolic disturbances, comprising:
3 administering to said individual an effective dosage of a composition selected from the
4 group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 9. (Withdrawn) The method of claim 8, wherein the individual has at least one
2 component of the Metabolic Syndrome.

1 10. (Withdrawn) A method for preventing chronic inflammation due to the presence of
2 or potential exposure to a pathogen, environmental particulates, or environmental toxins, said
3 method comprising: administering to said individual an effective dosage of a pharmaceutical
4 composition selected from the group consisting of YG-Product, YGG-Product, Purified
5 Leukocyte Dialysate Subfraction, and a combination thereof.

PATENT
P56874

1 11. (Withdrawn) A method for mitigating a symptom in a patient, said symptom
2 characteristic of chronic inflammation, said patient presenting said symptom, said method
3 comprising administering to the patient a pharmaceutical preparation containing an effective
4 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 12. (Withdrawn) The method of claim 11, wherein said patient has at least one
2 component of the Metabolic Syndrome.

1 13. (Withdrawn) The method of claim 12, wherein said symptom is at least one selected
2 from the group consisting of elevated blood pressure, atherogenic dyslipidemia, abdominal
3 obesity, insulin resistance with or without glucose intolerance, a proinflammatory state, and a
4 prothrombotic state.

1 14. (Withdrawn) A method for mitigating a symptom in a patient, said symptom
2 characteristic of an inflammation-related metabolic disturbance, said patient presenting said
3 symptom, said method comprising administering to the patient a pharmaceutical preparation
4 containing an effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte
5 Dialysate Subfraction, or a combination thereof.

1 15. (Withdrawn) The method of claim 14, wherein said patient has at least one
2 component of the Metabolic Syndrome.

PATENT
P56874

1 16. (Withdrawn) The method of claim 15, wherein said component is at least one
2 selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,
3 abdominal obesity, insulin resistance with or without glucose intolerance, a proinflammatory
4 state, and a prothrombotic state.

1 17. (Withdrawn) A method for deferring the progression of a patient from the Metabolic
2 Syndrome including Hypertension, to Diabetes Mellitus, Coronary Heart Disease, or Cancer,
3 said method comprising administering to the patient a pharmaceutical preparation containing an
4 effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate
5 Subfraction, or a combination thereof.

1 18. (Withdrawn) A method for preventing or mitigating development of inflammation-
2 related sequelae of exposure of a person to liquids or vapors containing organic solvents or
3 hydrocarbon fuels, or to environmental toxins capable of provoking chronic inflammation, said
4 method comprising:

5 (a) administering to the person a pharmaceutical preparation containing an effective
6 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
7 combination thereof;

8 (b) monitoring the person for immune function response, inflammation, and blood
9 glucose level; and

10 (c) continuing to administer to the patient said pharmaceutical preparation until the
11 person shows a normal immune function response and normal measures of inflammatory
12 parameters.